Key Takeaways
- FY26 was a foundational reset, not a growth year: Revenue fell 8% YoY as PI/API destocking masked a 23% surge in contrast media; management calls the year an investment-intensive bridge to the next growth phase.
- Contrast media is the near-term engine: Q4 revenue jumped 55% QoQ and 91% YoY on volume growth from an existing customer, and FY27 is guided for double-digit growth with 3-4 new product launches.
- PI/API destocking is over, recovery underway: The cardiovascular intermediate that drove the 35% segment decline has normalized; the plant is running at optimum capacity and shipments have resumed.
- A capex super-cycle is beginning: Vizag greenfield (₹1,000 cr over ~3 years), Mahad backward integration, and a Hyderabad R&D center all break ground or go live in FY27, with the stated ambition to double capacity and chemistry platforms.
- What to watch next quarter: Whether Q1 margins absorb the full freight and crude cost impact that March 2026 did not capture, and whether the 1-2 contrast media validations and 1 commercial launch materialize on schedule.
Contrast Media: The Quarter's Standout and FY27's Growth Driver
- Q4 revenue surge was volume, not price: The ₹190 cr top line (vs ₹125 cr in Q3) came entirely from the Q4 order book, driven by strong offtake from an existing customer on an existing product, plus contribution from an NCE intermediate commercialized in FY25; pricing is locked in long-term contracts.
- Customer offtake is lumpy by nature: Management cautioned against reading quarterly numbers linearly, noting that in this CDMO activity annual commitments are generally met but monthly or quarterly shipments are not uniform.
- FY27 launch pipeline is concrete: 3 to 4 new product launches are expected during the current year, comprising a combination of gadolinium and iodinated products; 1-2 validations and 1 commercial launch are the specific milestones.
- Growth is volume-led plus new launches: The double-digit FY27 growth expectation is backed by certain customer visibility and will be partially volume growth on existing products, partially contribution from new launches.
- Backward integration adds strategic heft: The Mahad Unit 3 plant, in final stages of completion, will produce a key raw material for the contrast media portfolio, with the primary objective of gaining strategic independence and avoiding volatility from importing from Europe or China; it goes onstream in H2 FY27 with a slow ramp-up.
Karuppannan: "In this particular CDMO activity, one should not look at a monthly or a quarterly. I think as long as we get that annual number right, I think that would be a better way to forecast."
PI/API: Destocking Over, Normalization Begins
- The 35% decline was a one-customer, one-molecule event: The entire segment drop was predominantly due to destocking by a customer for an intermediate for a cardiovascular drug; that inventory normalization has now occurred.
- Recovery is already visible: The plant is running to optimum capacity, shipments have started rolling out, and the company expects to normalize growth and exceed the FY25 peak sale for that cardiovascular drug intermediate.
- Pipeline is deep but conversion is the test: Of approximately 20 active RFPs, 2 are expected to move into commercialization during the current year; the segment is described as resilient despite geopolitical raw material price pressures, with pass-through mechanisms on pricing and margin security in some cases.
- Two lateral entry opportunities carry high conviction: Management is evaluating 2 commercial-stage opportunities that may evolve into strategic lateral entries; dedicated capacity is being factored into Vizag's long-term planning, with peak volumes expected to come much faster than for NCE products.
- End-market demand is a tailwind: The key molecule in CDMO PI shows fantastic growth at the final formulation level, and all three verticals (contrast media, CDMO PI, peptides) are sunrise segments with growing end markets.
Singh: "I think over the last 6 quarters, the work that has been happening, very intensive work has been happening, and we are getting to a stage when that will all start fructifying."
The Capex Super-Cycle: Vizag, Mahad, Hyderabad
- Vizag is the flagship bet: The 100-acre greenfield site has broken ground; Phase 1 will develop dedicated manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates, with a total outlay of ₹1,000 cr over approximately 3 years and ₹400 cr proposed for FY27 alone across all projects.
- Mahad backward integration goes live this year: The plant is in final stages of completion and expected to commence production in H2 FY27; beyond strategic independence, there will be incremental top-line opportunities selling the key raw material to third parties.
- Hyderabad R&D center targets the peptide opportunity: A ₹40 cr investment will focus on peptide-related intermediates, GLP-1 linked opportunities, biocatalysts, and faster CDMO turnaround; it is expected to go live in H2 FY27.
- Investment intensity stays high: FY27 will continue to be an investment-intensive year, with R&D spend also expected to increase as the Hyderabad center goes live; management frames FY26 as the year of sowing seeds for doubling both capacity and chemistry platforms.
Singh: "while FY26 might have been flattish, the year was foundational because we are sowing the seeds for doubling our capacity and doubling our chemistry platforms in R&D."
New Verticals: Peptides, Sweeteners, and the Japanese Trial
- Peptides start with building blocks: Lab supplies have begun to some innovators and large peptide CDMOs for building blocks and intermediates; the strategy is to gain clientele and experience with peptide fragments before advancing to final peptide manufacture, which management calls the natural corollary.
- Peptide margins are promising but price erosion is a known risk: Margins are expected to be very good (in line with or better than current), but management acknowledges there could be faster, higher price erosion in peptides compared to contrast media and patented CDMO segments where price erosion is not seen.
- Artificial sweetener validation is the gating item: One high-volume product is currently under validation, with trial quantities expected to ship over coming quarters; management calls delivering this key validation the most significant milestone and will share future updates only after quality targets, efficiencies, and yields are met.
- Japanese customer trial order shipped: A trial quantity has been shipped to a Japanese customer; clinical indications are described as extremely encouraging from a future growth perspective, though management declined to specify the product.
- A PE acquisition of an innovator partner is seen as positive: The end molecule is growing, the product is patent-protected with a regulatory pathway, and the stronger partner brings positive growth levers; business as usual.
Singh: "On the peptide side also, our starting point is doing the building blocks for the peptides or doing the peptide fragments... As we advance and we get clientele and we get experience in doing the peptide blocks, doing the final peptide will be the natural corollary."
Margins: Compressed in FY26, Q1 Will Set the Baseline for FY27
- FY26 margin compression was volume-driven: EBITDA margin fell to 31% from 37% due to lower volumes in the PI/API category; gross margin held relatively stable at 54% vs 55% in FY25, aided by rupee depreciation that improved export realizations and negated raw material price increases from the Iran war.
- Cost headwinds are emerging but not yet quantified: Freight costs post-March 2026 have increased, and crude oil price impacts, logistics costs, and domino effects were very limited in March 2026 and not fully seen; management explicitly declined to give a margin outlook, stating that Q1 will give a good representation of cost structures and margins.
- Pricing pass-through discussions are ongoing: The company is in discussions with customers on pricing pass-through, and in some cases already has pass-through mechanisms on pricing and margin security.
- Near-term optimization is not the priority: When pressed on whether the company is optimizing for the near term, management pointed to leading financial metrics being among the best in the industry and emphasized the investment phase.
Singh: "If you look at our leading financial metrics and indicators, I think they are one of the best in the industry. So I don't see why you should be asking that we are not optimizing for the near term."
Customer & Competitive Dynamics
- Bempedoic Acid intermediate enjoys a narrow competitive field: The molecule is still under patent, so few suppliers exist; Blue Jet's competitive edge comes from advanced intermediate complexity, the regulatory pathway, a dedicated highly automated plant, strong unit operations, and scale.
- A customer warning letter is not disrupting offtake: One customer received a warning letter for their sole formulation plant in October; management says it is not reflecting in production schedules or offtake requirements, business as usual, with no disruption foreseen in coming quarters.
- The company is debt-free and may raise funds: Asked about funding the Vizag investment, management said the situation is dynamic and will update in coming quarters, but noted the company is well positioned as a debt-free entity accelerating its capex plan.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Contrast media growth | Double-digit growth in FY27, backed by certain customer visibility | FY27 |
| Contrast media new launches | 3 to 4 new product launches; 1-2 validations and 1 commercial launch | FY27 |
| PI/API recovery | Normalize growth and grow over FY25 peak sale for the cardiovascular drug intermediate | FY27 |
| PI/API pipeline conversion | 2 of ~20 active RFPs expected to move into commercialization | FY27 |
| Mahad backward integration | Plant commences production; slow ramp-up | H2 FY27 |
| Hyderabad R&D center | Goes live, focused on peptides, GLP-1, biocatalysts | H2 FY27 |
| Vizag greenfield Phase 1 | Manufacturing blocks for contrast media, sweeteners, pharma intermediates | 24-30 months from now |
| FY27 capex | ₹400 cr across Vizag, Mahad completion, and Ambernath | FY27 |
| Margin visibility | Q1 will give a good representation of cost structures and margins | Q1 FY27 |
| Artificial sweetener | Deliver key validation; trial quantities to ship | Coming quarters |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹235 cr, +22% QoQ and -31% YoY |
| Contrast media revenue | ₹193 cr, +55% QoQ and +91% YoY |
| PI/API revenue | ₹2.4 cr, vs ₹40 cr in Q3 and ₹196 cr in Q4 FY25 |
| Artificial sweetener revenue | ₹37 cr, +43% QoQ and -24% YoY |
| Gross margin | 56%, vs 52% in Q3 and 55% in Q4 FY25 |
| FY26 full-year revenue | ₹947 cr, -8% vs FY25 |
| FY26 full-year contrast media revenue | ₹495 cr, +23% vs FY25 |
| FY26 full-year PI/API revenue | ₹298 cr, -35% vs FY25 |
| FY26 full-year artificial sweetener revenue | ₹131 cr, -2% vs FY25 |
| FY26 full-year gross margin | 54%, vs 55% in FY25 |
| FY26 EBITDA margin | 31%, vs 37% in FY25 |
| FY26 PAT margin | 26%, vs 30% in FY25 |
| FY26 other income | ₹69 cr, vs ₹46 cr in FY25, includes exchange gain of ₹36 cr and insurance claim income of ₹5 cr |
| FY26 cash flow from operating activities | ₹334 cr |
| Liquid financial assets at FY26 end | ₹400 cr, vs ₹306 cr in FY25, debt-free |
| Total CWIP as of March 2026 | ₹301 cr, predominantly Mahad and Vizag land acquisition |
| Proposed capex for FY27 | approximately ₹400 cr, for Vizag greenfield, Mahad completion, and Ambernath additions |
| Vizag total capex plan | approximately ₹1,000 cr over approximately 3 years |
| Hyderabad R&D center planned investment | approximately ₹40 cr |
| Contrast media FY27 annual forecast from customer | mid-single digit growth |
| Energy consumption from renewables | 70% |
| Contrast media new product launches expected in FY27 | 3 to 4 |
| Active RFPs in PI and CDMO segment | approximately 20, primarily chronic therapeutic areas including GLP-1 and peptide building blocks |
| PI/CDMO opportunities expected to commercialize in FY27 | 2 |
| High conviction commercial stage lateral entry opportunities | 2, dedicated capacity factored into Vizag planning |